European Interleukin Inhibitors Market Hits $10,316.4 Million in 2025 with 9.2% CAGR

European interleukin inhibitors market was valued at $10,316.4 million in 2025 and is projected to reach $24,800.6 million by 2035, growing at a CAGR of 9.2% during the forecast period (2026–2035). Interleukin inhibitors are biologic therapies designed to target specific inflammatory pathways such as IL-17, IL-23, IL-6, and IL-1, and are widely used in the treatment of autoimmune and chronic inflammatory disorders including psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease. Market growth is driven by the rising prevalence of immune-mediated diseases, increasing adoption of targeted biologics over conventional systemic therapies, and expanding reimbursement coverage across major European healthcare systems.

Browse the full report description of “European Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/europe-interleukin-inhibitors-market

The market is experiencing robust expansion across Europe, supported by strong clinical evidence, early adoption of advanced biologic therapies, and well-established specialty care infrastructure. Key trends shaping the interleukin inhibitors landscape include the growing shift toward next-generation IL-17 and IL-23 inhibitors, increased uptake of subcutaneous self-administration formulations, and rising focus on biosimilars to improve treatment affordability. In addition, ongoing real-world evidence generation, favorable regulatory pathways by the EMA, and strategic collaborations between pharmaceutical companies and research institutions are collectively fueling sustained market momentum.

According to PMC and the European Medicines Agency (EMA), the adoption and clinical utilization of interleukin (IL) inhibitors in Europe is expanding as clinicians increasingly rely on these targeted biologic therapies to treat chronic inflammatory and autoimmune diseases such as psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis.

Key Innovators Driving European Interleukin Inhibitors Transformation

The key players in the European interleukin inhibitors market include AbbVie Inc., Amgen Inc., Eli Lilly and Company, Novartis AG, and Sanofi S.A., among others. These companies are advancing innovation through novel cytokine-targeted biologics, expanded indications, and patient-centric delivery platforms, shaping the future of autoimmune disease management across Europe.

• In July 2025, Novartis AG of Switzerland announced the expansion of its IL-17 inhibitor portfolio in Europe with the initiation of new Phase III clinical trials for patients with moderate to severe psoriasis and psoriatic arthritis. The initiative is aimed at broadening therapeutic indications and reinforcing the company’s leadership in interleukin-targeted therapies across the region.
• In May 2025, Roche Holding AG of Switzerland received European regulatory approval for its IL-6 inhibitor for the treatment of rheumatoid arthritis, representing a significant step in expanding patient access to advanced biologic therapies.
• In March 2025, Sanofi of France launched a regional program to enhance the distribution and accessibility of its IL-23 inhibitor across major European markets, supported by physician education and patient assistance initiatives. Collectively, these developments underscore increasing adoption, clinical expansion, and strategic investment in interleukin inhibitors throughout Europe.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product Type
  • By Application
• Competitive Landscape - AbbVie Inc., Amgen Inc., Eli Lilly and Company, Novartis AG, and Sanofi S.A., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

European Interleukin Inhibitors Market Report Segment

By Product Type

• IL-1 Inhibitors
• IL-5 Inhibitors
• IL-6 Inhibitors
• IL-17 Inhibitors
• IL-23 Inhibitors

By Application

• Arthritis
• Asthma
• Eczema
• Inflammatory Bowel Disease (IBD)
• Psoriasis
• Others

European Interleukin Inhibitors Market Report Segment by Country

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/europe-interleukin-inhibitors-market